IDEC’s 1999 Press Releases

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission (“SEC”) or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press releases and filings with the SEC.

2003 | 2002 | 2001 | 2000 | 1999

Back to main index


Results of Four ZEVALIN Clinical Studies Presented At ASH


New Data From Key Rituxan Clinical Studies Presented At 41st Annual Society of Hematology Meeting


IDEC Pharmaceuticals Announces 2-for-1 Common Stock Split


Genentech and IDEC Pharmaceuticals to Receive 1999 Trailblazers Award From Cure for Lymphoma Foundation


IDEC Pharmaceuticals Reports Third Quarter 1999 Results; IDEC’s Board of Directors Approves a 2-for-1 Stock Split


IDEC Pharmaceuticals Begins Phase I/II Study in Psoriasis With PRIMATIZED Antibody, IDEC-114

2003 | 2002 | 2001 |2000 | 1999